Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prophase Labs Inc (NQ: PRPH )

4.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 4.900
Bid (Size) 4.750 (10)
Ask (Size) 6.100 (4)
Prev. Close 4.900
Today's Range 4.900 - 4.900
52wk Range 4.050 - 9.941
Shares Outstanding 16,277,764
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PRPH Stock Earnings: ProPhase Labs Misses EPS, Misses Revenue for Q4 2023
PRPH stock results show that ProPhase Labs missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Earnings Scheduled For March 15, 2024
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million. 
Via Benzinga

Performance

YTD
+5.60%
+5.60%
1 Month
-20.97%
-20.97%
3 Month
-4.11%
-4.11%
6 Month
+7.93%
+7.93%
1 Year
-37.42%
-37.42%

More News

Read More
ProPhase Labs's Earnings: A Preview
Via Benzinga
ProPhase Labs Earnings Preview
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Analyst Expectations for ProPhase Labs's Future
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
DSS, Inc.'s (NYSE American: DSS) Subsidiary Appoints New Chief Investment Officer To Aggressively Develop Mutual Fund Business For Eventual Spinoff
Via Benzinga
DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement
Via News Direct
Recap: ProPhase Labs Q1 Earnings
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
ProPhase Labs Earnings Preview
Via Benzinga
Earnings Scheduled For August 10, 2023
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement
Via TheNewswire.com
DSS Inc. Is Spinning Off Its Biotech Subsidiary After Signing A Major Licensing Agreement
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
Via InvestorPlace
Impact Biomedical Preparing A Potential Spinoff — What Does This Mean For Investors Of Holding Company DSS, Inc (NYSE American: DSS)?
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
ProPhase Labs's Return On Capital Employed Overview
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022
From ProPhase Labs, Inc.
Via GlobeNewswire
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
From ProPhase Labs, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.